Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

JAZZ PHARMACEUTICALS

Filed by TIBER CREEK GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 19, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
40759050-9cbc-4ef7-a117-c9d75dd53bce
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.

MED · Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

BUD · Budget/Appropriations

Issues related to House Ag/FDA Appropriations pertaining to FDA enforcement of non-FDA approved, cannabis derived CBD products; Issues related to the Ag/FDA amendment - technical correction to the 2026 Ag/FDA appropriations bill related to hemp; Issues related to intoxicating hemp products.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.